drugset / Trial / NCT02709343
Trial of Bone-marrow Derived Mesenchymal Stromal Cells (MSC) for New Onset Chronic Lung Allograft Dysfunction
Phase 2
Completed
64 enrolled
The University of Queensland
Cell and Tissue Therapies · collabIsopogen · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
This study is designed for lung transplant patients who have developed chronic lung allograft dysfunction (CLAD). Consented patients will receive 4 intravenous doses of allogeneic, bone-marrow-derived MSCs (2\*10\^6 cells/kg/dose) or matching placebo over a period of 2 weeks with a 12 month follow up.
Timeline
- Start
- 2017-04-21
- Primary completion
- 2023-09-13
- Completion
- 2023-10-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bone Marrow Aspirate | Cell therapy | 2e+06 cells/kg | Intravenous |